Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Core Insights - Acurx Pharmaceuticals, Inc. (ACXP) has shown strong year-to-date performance compared to its Medical sector peers, returning 14.9% against the sector average of 5.4% [4] - The Zacks Rank for Acurx Pharmaceuticals is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past 90 days, the consensus estimate for ACXP's full-year earnings has increased by 22.7%, reflecting improved analyst sentiment [4] Company Performance - Acurx Pharmaceuticals is part of the Medical group, which includes 934 companies and ranks 5 in the Zacks Sector Rank [2] - In the Medical - Biomedical and Genetics industry, which consists of 455 companies, Acurx ranks 105, slightly underperforming the industry average return of 15.5% [6] - Adial Pharmaceuticals, Inc. (ADIL) is another Medical stock that has outperformed the sector, returning 16% year-to-date and also holding a Zacks Rank of 2 (Buy) [5] Analyst Sentiment - The Zacks Consensus Estimate for Adial Pharmaceuticals' current year EPS has increased by 31.6% over the past three months, indicating strong analyst confidence [5] - Investors are encouraged to monitor both Acurx Pharmaceuticals and Adial Pharmaceuticals for their continued solid performance in the Medical sector [7]